Success Stories: NIW Petition Approved for a Senior Scientist from China in the Field of Pharmaceutical Sciences in 1 Month, 21 Days, Thanks to Our Team’s Dedication and the Premium Processing Service
Client’s Testimonial:
“It has also been a great experience working with your firm.”
On March 17th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Scientist in the Field of Developmental Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Senior Scientist
Country of Origin: China
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: March 17th, 2025
Processing Time: 1 month, 21 days (Premium Processing Requested)
Case Summary:
Based on the huge number of successful cases, North America Immigration Law Group has developed the most up-to-date winning strategies for the NIW category, which enable us to offer our “Approval or Refund” services to many of the NIW cases we take. However, there are certain prerequisites to be fulfilled by an individual, including:
- The foreign national must be in a position to advance the proposed endeavor.
- The applicant must present evidence that the U.S. would benefit on balance to waive the job offer criteria for an EB-2.
- A proposed endeavor, holding substantial merit and national importance.
Our client, a senior scientist from China, approached us to file an NIW (National Interest Waiver Petition) on his behalf.
He has completed his Ph.D. in pharmaceutical sciences, and as an expert in the field of pharmaceutical sciences, his proposed endeavor is to develop novel and advanced drug delivery systems for new drug products to support animal studies and clinical trials in a wide scope of treatment indications.
Therefore, to make a persuasive case in his favor, we included the following details in his petition packet:
- His work has resulted in 9 peer-reviewed journal articles (1 of them first-authored), 1 first-authored book chapter, and 1 accepted first-authored book chapter.
- His publications have been cited a total of 130 times, according to Google Scholar.
Our client’s research advancing his proposed endeavor addresses the need for improved treatment of CVDs, which are the primary global cause of death and claim approximately 17.9 million lives annually. By creating innovative methods to deliver drugs more effectively, his research improves the bioavailability, precision, and controlled release of medications. His advancements support animal studies and clinical trials, ensuring that new therapies reach their intended targets with greater efficiency. Ultimately, our client’s innovations pave the way for more effective treatments, addressing the global burden of CVD-related deaths
On that account, he received her NIW approval in 1 month and 21 days only. We wish him good luck in his upcoming endeavor.

